시장보고서
상품코드
1826985

세계의 신부전증 시장 보고서(2025년)

Renal Insufficiency Global Market Report 2025

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

신부전증 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 108억 7,000만 달러, 2025년에는 121억 달러에 달하고, CAGR 11.4%로 성장할 전망입니다. 성과기간 성장은 고혈압과 당뇨병 사례 증가, 만성 신장병(CKD) 유병률 증가, 요로 폐색 유병률 증가, 인구 고령화, 신장 건강 의식과 교육 증가로 인한 것으로 보입니다.

신부전증 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 11.2%로 185억 2,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 급성신장해(AKI)의 유병률 증가, 재택치료 옵션의 채택 증가, 헬스케어 지출의 급증, 연구개발 투자에 기인한다고 생각됩니다. 예측기간의 주요 동향으로는 의료기술의 진보, 기술과 치료 옵션의 진보, 맞춤형 의료의 통합, 투석기술의 진보, 새롭고 혁신적인 약제의 개발 등이 있습니다.

신부전증은 노폐물을 여과하고 신체의 수분과 전해질의 균형을 유지하는 신장의 기능이 저하된다는 것을 의미합니다. 당뇨병, 고혈압, 급성 신장 질환 등의 만성 질환으로 인해 혈액에 독소가 축적 될 수 있습니다. 신부전증을 치료하지 않고 방치하면 만성 신장병(CKD)이나 신부전증으로 진행되어 투석이나 이식이 필요할 수 있습니다.

신부전증의 주요 치료법에는 약물 요법, 투석, 신장 이식 및 기타 치료법이 있습니다. 약물 요법은 증상을 관리하고 질병의 진행을 늦추고 고혈압, 당뇨병, 빈혈 등의 합병증을 치료하는 데 도움이 됩니다. 병리학은 만성 신장 질환(CKD)의 단계와 말기 신장 질환(ESRD)과 같은 다양한 단계를 거쳐 진행됩니다. 치료는 병원 약국, 소매 약국, 온라인 약국을 통해 유통되며 최종 사용자는 투석 센터, 병원, 클리닉, 연구 및 학술 기관을 포함합니다.

2025년 봄 미국 관세의 급상승과 이에 따른 무역 마찰은 의료 분야, 특히 필수적인 의료기기, 진단 장비 및 의약품 공급에 큰 영향을 미쳤습니다. 병원과 건강 관리 제공업체는 수입되는 수술 기구, 영상 진단 시스템, 주사기 및 카테터와 같은 소모품의 비용 상승에 시달리고 있으며, 그 대부분은 국내 대체품이 제한되어 있습니다. 이러한 비용 상승이 의료 예산을 압박하기 때문에 일부 의료기관은 장비 업그레이드를 늦추거나 비용 증가를 환자에게 전가하고 있습니다. 게다가 원료와 부품에 대한 관세는 중요한 의약품과 의료기기의 제조에 지장을 주고 공급망의 지연으로 이어지고 있습니다. 이에 비해 업계는 다양한 조달 전략을 채택하고 가능한 한 현지 생산을 확대하고 중요한 의료 제품의 관세 면제를 수행하고 있습니다.

이 조사 보고서는 신부전증 업계 세계 시장 규모, 지역 점유율, 신부전증 시장 점유율을 가진 경쟁업체, 상세한 신부전증 시장 부문, 시장 동향 및 비즈니스 기회, 신부전증 업계에서 성공하는 데 필요한 데이터 등 신부전증 시장 통계를 제공하는 The Business Research Company의 신간 보고서 시리즈 중 하나입니다. 이 신부전증 시장 조사 보고서는 업계의 현재 및 미래 시나리오를 자세히 분석하고 필요한 모든 것을 완벽한 관점에서 제공합니다.

향후 5년간의 성장률 11.2%라고 하는 예측은 전회의 예측으로부터 0.2%의 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 인상은 일본과 독일에서 조달하는 높은 유량의 혈액 투석 필터와 초순수 시스템의 비용을 증가시키고, 치료비를 악화시키고, 신장 내과의 치료 부담을 증가시키기 때문에 미국의 투석 센터에 부담을 강하게 할 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

고혈압과 당뇨병의 유병률 증가는 앞으로 수년간 신부전증 시장의 성장을 이끌 것으로 예측됩니다. 이러한 질병은 식생활 교란, 운동 부족, 비만, 유전적 소인, 노화 등의 요인에 영향을 받습니다. 고혈압은 흉터를 일으켜 여과능력을 저하시킴으로써 신혈관에 손상을 주고, 당뇨병은 혈당의 상승에 의해 신혈관을 비후시켜 혹사합니다. 두 병태 모두 신장 손상을 가속화시켜 결국 신부전증을 초래합니다. 예를 들어 2024년 5월 영국 정부기관인 국민보건서비스(NHS)는 2023년 12월 남동부의 고혈압 진단 환자 수가 7만 1,120명 증가하고 2022년 12월에 비해 5.4% 증가했다고 보고했습니다. 또한 영국을 거점으로 하는 자선단체인 영국 당뇨병협회는 2023년 4월 영국에서 430만명이 당뇨병으로 진단되었다고 발표했습니다. 그 결과 고혈압과 당뇨병의 유병률 증가가 신부전증 시장 확대에 박차를 가하고 있습니다.

신부전증 시장의 주요 기업은 당뇨병 및 만성 신장병(CKD) 환자의 신장 및 심혈관 합병증을 다루기 위해 글루카곤-유사 펩티드-1 수용체 작용제(GLP-1 RA)의 개발에 주력하고 있습니다. 이 약물은 포도당 조절을 강화하고 염증을 억제하며 신장의 산화 스트레스를 낮추어 신부전증의 진행을 지연시킵니다. 예를 들어, 2025년 1월, 덴마크에 본사를 두고 있는 제약회사 Novo Nordisk사는 2형 당뇨병과 CKD를 가진 성인에서 신장병의 진행, 신부전증 및 심혈관사 위험을 줄이는 오젠픽(세마글루티드)에 대해 식품의약국(FDA)의 승인을 취득했습니다. 이 승인은 당뇨병과 신부전증을 관리하는 이중 접근법을 제공하고 진행성 CKD 환자의 주요 암멧 의료 요구에 대응하는 GLP-1 RA의 역할이 증가하고 있음을 강조합니다.

2023년 2월 영국 제약 회사인 AstraZeneca PLC는 CinCor Pharma Inc.를 18억 달러로 인수했습니다. 이 인수는 치료 저항성 고혈압 환자의 혈압 강하를 목표로 하는 알도스테론 합성효소 억제제 baxdrostat(CIN-107)를 통합하여 아스트라제네카의 심신계 포트폴리오를 강화시켰습니다. CinCor Pharma Inc.는 미국에 본사를 둔 임상 단계의 바이오 의약품 회사로 중등도에서 중증 신장 장애 또는 신부전증 환자에 대한 치료법 개발에 주력하고 있습니다.

신부전증 시장은 투석 장비, 신장 대체 요법, 신장 이식 서비스, 신장 기능 관리를위한 의약품 치료의 판매로 구성됩니다. 이 시장의 가치는 '팩토리 게이트(공장 출하 시)' 가치, 즉 다른 기업(다운스트림 제조업자, 도매업체, 유통업체, 소매업체 포함)이든 직접 최종 고객이든, 상품 제조업체 또는 제조업체가 판매한 상품의 가치입니다. 이 시장에서 상품의 가치에는 상품 제작자에 의해 판매되는 관련 서비스도 포함됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

  • 세계 신부전증 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
  • 최종 이용 산업의 분석
  • 세계 신부전증 시장 : 성장률 분석
  • 세계 신부전증 시장 실적 : 규모와 성장, 2019-2024
  • 세계 신부전증 시장 예측 : 규모와 성장, 2024-2029, 2034F
  • 세계 신부전증 : 전체 시장 규모(TAM)

제6장 시장 세분화

  • 세계 신부전증 시장 : 치료유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 의약품
  • 투석
  • 신장 이식
  • 기타 치료 유형
  • 세계 신부전증 시장 : 질병 단계별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 만성 신장병(CKD)의 스테이지
  • 말기신질환(ESRD)
  • 세계 신부전증 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 병원 약국
  • 소매 약국
  • 온라인 약국
  • 세계 신부전증 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 투석 센터
  • 병원 및 진료소
  • 조사·학술 기관
  • 세계 신부전증 시장 : 세분화 의약품(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 안지오텐신 전환효소(ACE) 억제제
  • 안지오텐신 II 수용체 길항제(ARB)
  • 이뇨제
  • 적혈구 조혈 자극 인자(ESA)
  • 인산 결합제
  • 중탄산나트륨
  • 세계 신부전증 시장 : 세분화 투석 유형, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 혈액 투석
  • 복막 투석
  • 재택 투석
  • 지속적 신 대체요법(CRRT)
  • 세계 신부전증 시장 : 세분화 신장 이식 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 생체 기증자 신장 이식
  • 뇌사 기증자에 의한 신장 이식
  • 신장 이식 면역 억제 요법
  • 세계 신부전증 시장 : 세분화 기타 치료 유형(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 라이프 스타일과 식생활 개선
  • 줄기세포요법
  • 유전자 치료

제7장 지역별/국가별 분석

  • 세계 신부전증 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 세계 신부전증 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

  • 신부전증 시장 : 경쟁 구도
  • 신부전증 시장 : 기업 프로파일
    • Kaiser Permanente : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Roche Holding AG : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Abbott Laboratories : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

  • Medtronic plc
  • Amgen Inc.
  • Asahi Kasei Medical Co. Ltd.
  • Fujifilm Holdings Corporation
  • Fresenius Medical Care
  • Toray Industries Inc.
  • Baxter International Inc.
  • Boehringer Ingelheim
  • DaVita Inc.
  • Eisai Co. Ltd.
  • Nipro Corporation
  • Biocon Limited
  • HemoCue AB
  • Rockwell Medical
  • Mitsubishi Tanabe Pharma Corporation

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

  • 신부전증 시장 2029 : 새로운 기회를 제공하는 국가
  • 신부전증 시장 2029 : 새로운 기회를 제공하는 부문
  • 신부전증 시장 2029 : 성장 전략
    • 시장 동향에 기초한 전략
    • 경쟁 전략

제36장 부록

SHW 25.10.17

Renal insufficiency refers to the decreased ability of the kidneys to filter waste products and maintain fluid and electrolyte balance in the body. It can result from chronic conditions such as diabetes, hypertension, or acute kidney injury, leading to toxin buildup in the blood. If left untreated, renal insufficiency may progress to chronic kidney disease (CKD) or kidney failure, necessitating dialysis or transplantation.

The primary treatment options for renal insufficiency include medications, dialysis, kidney transplantation, and other interventions. Medications help manage symptoms, slow disease progression, and address complications such as high blood pressure, diabetes, and anemia. The condition progresses through different stages, including chronic kidney disease (CKD) stages and end-stage renal disease (ESRD). Treatment is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, with end-users including dialysis centers, hospitals, clinics, and research and academic institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The renal insufficiency market research report is one of a series of new reports from The Business Research Company that provides renal insufficiency market statistics, including renal insufficiency industry global market size, regional shares, competitors with a renal insufficiency market share, detailed renal insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the renal insufficiency industry. This renal insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The renal insufficiency market size has grown rapidly in recent years. It will grow from $10.87 billion in 2024 to $12.1 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to increasing cases of high blood pressure and diabetes, increasing prevalence of chronic kidney disease (CKD), rising prevalence of obstructions in the urinary tract, aging population, and increasing awareness and education regarding kidney health.

The renal insufficiency market size is expected to see rapid growth in the next few years. It will grow to $18.52 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to increasing prevalence of acute kidney injuries (AKI), increasing adoption of home-based treatment options, surge in healthcare expenditure, and investments in research and development. Major trends in the forecast period include advancements in medical technology, advancements in technology and treatment options, integration of personalized medicine, advancements in dialysis technology, and development of new and innovative medications.

The forecast of 11.2% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. dialysis centers by driving up costs of high-flux hemodialysis filters and ultrapure water systems sourced from Japan and Germany, exacerbating treatment expenses and increasing nephrology care burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of high blood pressure and diabetes is expected to drive the growth of the renal insufficiency market in the coming years. These conditions are influenced by factors such as poor diet, lack of physical activity, obesity, genetic predisposition, and an aging population. High blood pressure damages kidney blood vessels by causing scarring and reducing filtration capacity, while diabetes leads to thickened and overworked kidney vessels due to elevated blood sugar levels. Both conditions accelerate kidney damage, ultimately resulting in renal insufficiency. For example, in May 2024, the National Health Service (NHS), a UK-based government agency, reported that the number of high blood pressure diagnoses in the South East increased by 71,120 patients in December 2023, marking a 5.4% rise compared to December 2022. Additionally, in April 2023, the British Diabetic Association, a UK-based charity organization, stated that 4.3 million people in the UK had been diagnosed with diabetes. Consequently, the increasing prevalence of high blood pressure and diabetes is fueling the expansion of the renal insufficiency market.

Leading companies in the renal insufficiency market are focusing on the development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to address renal and cardiovascular complications in patients with diabetes and chronic kidney disease (CKD). These medications enhance glucose control, reduce inflammation, and lower oxidative stress in the kidneys, thereby slowing the progression of renal insufficiency. For example, in January 2025, Novo Nordisk, a Denmark-based pharmaceutical company, received Food and Drug Administration (FDA) approval for Ozempic (semaglutide) to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD. This approval underscores the growing role of GLP-1 RAs in providing a dual approach to managing diabetes and renal insufficiency, addressing key unmet medical needs for patients with progressive CKD.

In February 2023, AstraZeneca PLC, a UK-based pharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. This acquisition enhances AstraZeneca's cardiorenal portfolio by incorporating baxdrostat (CIN-107), an aldosterone synthase inhibitor designed to lower blood pressure in patients with treatment-resistant hypertension. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company focused on developing treatments for individuals with moderate to severe renal impairment or kidney failure.

Major players in the renal insufficiency market are Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation, and Sorin Group.

North America was the largest region in the renal insufficiency market in 2024. The regions covered in renal insufficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the renal insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The renal insufficiency market consists of sales of dialysis equipment, renal replacement therapies, kidney transplantation services, and pharmaceutical treatments for managing kidney function. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Renal Insufficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on renal insufficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for renal insufficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The renal insufficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment Type: Medications; Dialysis; Kidney Transplantation; Other Treatment Types
  • 2) By Disease Stage: Chronic Kidney Disease (CKD) Stages; End-Stage Renal Disease (ESRD)
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 4) By End-User: Dialysis Centers; Hospital And Clinics; Research And Academic Institutes
  • Subsegments:
  • 1) By Medications: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Diuretics; Erythropoiesis-Stimulating Agents (ESAs); Phosphate Binders; Sodium Bicarbonate
  • 2) By Dialysis: Hemodialysis; Peritoneal Dialysis; Home Dialysis; Continuous Renal Replacement Therapy (CRRT)
  • 3) By Kidney Transplantation: Living Donor Kidney Transplant; Deceased Donor Kidney Transplant; Kidney Transplant Immunosuppressive Therapy
  • 4) By Other Treatment Types: Lifestyle And Dietary Modifications; Stem Cell Therapy; Gene Therapy
  • Companies Mentioned: Kaiser Permanente; Johnson & Johnson; Roche Holding AG; Sanofi S.A.; Abbott Laboratories; Medtronic plc; Amgen Inc.; Asahi Kasei Medical Co. Ltd.; Fujifilm Holdings Corporation; Fresenius Medical Care; Toray Industries Inc.; Baxter International Inc.; Boehringer Ingelheim; DaVita Inc.; Eisai Co. Ltd.; Nipro Corporation; Biocon Limited; HemoCue AB; Rockwell Medical; Mitsubishi Tanabe Pharma Corporation; Sorin Group.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Renal Insufficiency Market Characteristics

3. Renal Insufficiency Market Trends And Strategies

4. Renal Insufficiency Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Renal Insufficiency Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Renal Insufficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Renal Insufficiency Market Growth Rate Analysis
  • 5.4. Global Renal Insufficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Renal Insufficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Renal Insufficiency Total Addressable Market (TAM)

6. Renal Insufficiency Market Segmentation

  • 6.1. Global Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Medications
  • Dialysis
  • Kidney Transplantation
  • Other Treatment Types
  • 6.2. Global Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chronic Kidney Disease (CKD) Stages
  • End-Stage Renal Disease (ESRD)
  • 6.3. Global Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.4. Global Renal Insufficiency Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Dialysis Centers
  • Hospital And Clinics
  • Research And Academic Institutes
  • 6.5. Global Renal Insufficiency Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
  • Angiotensin II Receptor Blockers (ARBs)
  • Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Phosphate Binders
  • Sodium Bicarbonate
  • 6.6. Global Renal Insufficiency Market, Sub-Segmentation Of Dialysis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hemodialysis
  • Peritoneal Dialysis
  • Home Dialysis
  • Continuous Renal Replacement Therapy (CRRT)
  • 6.7. Global Renal Insufficiency Market, Sub-Segmentation Of Kidney Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Living Donor Kidney Transplant
  • Deceased Donor Kidney Transplant
  • Kidney Transplant Immunosuppressive Therapy
  • 6.8. Global Renal Insufficiency Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lifestyle And Dietary Modifications
  • Stem Cell Therapy
  • Gene Therapy

7. Renal Insufficiency Market Regional And Country Analysis

  • 7.1. Global Renal Insufficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Renal Insufficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Renal Insufficiency Market

  • 8.1. Asia-Pacific Renal Insufficiency Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Renal Insufficiency Market

  • 9.1. China Renal Insufficiency Market Overview
  • 9.2. China Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Renal Insufficiency Market

  • 10.1. India Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Renal Insufficiency Market

  • 11.1. Japan Renal Insufficiency Market Overview
  • 11.2. Japan Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Renal Insufficiency Market

  • 12.1. Australia Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Renal Insufficiency Market

  • 13.1. Indonesia Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Renal Insufficiency Market

  • 14.1. South Korea Renal Insufficiency Market Overview
  • 14.2. South Korea Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Renal Insufficiency Market

  • 15.1. Western Europe Renal Insufficiency Market Overview
  • 15.2. Western Europe Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Renal Insufficiency Market

  • 16.1. UK Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Renal Insufficiency Market

  • 17.1. Germany Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Renal Insufficiency Market

  • 18.1. France Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Renal Insufficiency Market

  • 19.1. Italy Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Renal Insufficiency Market

  • 20.1. Spain Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Renal Insufficiency Market

  • 21.1. Eastern Europe Renal Insufficiency Market Overview
  • 21.2. Eastern Europe Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Renal Insufficiency Market

  • 22.1. Russia Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Renal Insufficiency Market

  • 23.1. North America Renal Insufficiency Market Overview
  • 23.2. North America Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Renal Insufficiency Market

  • 24.1. USA Renal Insufficiency Market Overview
  • 24.2. USA Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Renal Insufficiency Market

  • 25.1. Canada Renal Insufficiency Market Overview
  • 25.2. Canada Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Renal Insufficiency Market

  • 26.1. South America Renal Insufficiency Market Overview
  • 26.2. South America Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Renal Insufficiency Market

  • 27.1. Brazil Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Renal Insufficiency Market

  • 28.1. Middle East Renal Insufficiency Market Overview
  • 28.2. Middle East Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Renal Insufficiency Market

  • 29.1. Africa Renal Insufficiency Market Overview
  • 29.2. Africa Renal Insufficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Renal Insufficiency Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Renal Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Renal Insufficiency Market Competitive Landscape And Company Profiles

  • 30.1. Renal Insufficiency Market Competitive Landscape
  • 30.2. Renal Insufficiency Market Company Profiles
    • 30.2.1. Kaiser Permanente Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Renal Insufficiency Market Other Major And Innovative Companies

  • 31.1. Medtronic plc
  • 31.2. Amgen Inc.
  • 31.3. Asahi Kasei Medical Co. Ltd.
  • 31.4. Fujifilm Holdings Corporation
  • 31.5. Fresenius Medical Care
  • 31.6. Toray Industries Inc.
  • 31.7. Baxter International Inc.
  • 31.8. Boehringer Ingelheim
  • 31.9. DaVita Inc.
  • 31.10. Eisai Co. Ltd.
  • 31.11. Nipro Corporation
  • 31.12. Biocon Limited
  • 31.13. HemoCue AB
  • 31.14. Rockwell Medical
  • 31.15. Mitsubishi Tanabe Pharma Corporation

32. Global Renal Insufficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Renal Insufficiency Market

34. Recent Developments In The Renal Insufficiency Market

35. Renal Insufficiency Market High Potential Countries, Segments and Strategies

  • 35.1 Renal Insufficiency Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Renal Insufficiency Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Renal Insufficiency Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제